Therapeutic method using tolerogenic peptides
AssigneeApitope International NV
InventorsDavid Wraith, Keith Martin
Life of this patent
Estimating the term…
Abstract
The present invention relates to a therapeutic method using a tolerogenic peptide. In particular, the invention relates to a dosage regimen fora tolerogenic peptide. The therapeutic method can be used to treat or prevent conditions associated with aberrant, hypersensitivityor pathological immune responses to endogenous or exogenous proteins that results in a loss of immune tolerance.
Claims23
A method of treating or preventing in a subject a condition associated with aberrant immune tolerance (autoimmune disease), comprising administering to the patient a tolerogenic peptide via a dose escalation protocol in the following doses:
- Day 1:
- a first dose of about 15 to about 40 μg;
- Day 14±7 days:
- a second dose of about 35-65 μg;
- Day 28±7 days:
- a third dose of about 80-120 μg;
- Day 42±7 days:
- a fourth dose of about 300-500 μg;
- Day 56±7 days:
- a fifth dose of about 600-1500 μg;
- Day 70±7 days:
- a sixth dose of about 600-1500 μg;
- Day 84±7 days:
- a seventh dose of about 600-1500 μg;
- Day 98±7 days:
- an eighth dose of about 600-1500 μg;
- Day 112±7 days:
- a ninth dose of about 600-1500 μg;
- and
- Day 126±7 days:
- a tenth dose of about 600-1500 μg.
(canceled)
-25. (canceled)
Dependencies are inferred from the claim text.